重组人脑利钠肽治疗冠心病失代偿性心力衰竭的安全性及有效性

Safety and Efficacy of Recombinant Human Brain Natriuretic Peptide in the Treatment of Decompensated Heart Failure of Coronary Heart Disease

目的研究重组人脑利钠肽(rh-BNP)治疗冠心病失代偿性心力衰竭(DHF)的安全性及有效性。方法选取2020年12月-2022年12月萍乡市第三人民医院收治的60例冠心病DHF患者,按照随机数字表法分为对照组(30例)与观察组(30例),对照组行常规治疗,观察组在其基础上应用rh-BNP治疗,比较两组临床疗效、体征指标[心率(HR)、平均动脉压(MAP)、24h尿量]、心功能[左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、心输出量(CO)]、病情程度[西雅图心绞痛量表(SAQ)、心力衰竭症状状态问卷(SSQ-HF)]及不良反应。结果观察组治疗有效率(90.00%)高于对照组(73.33%)(P<0.05)。两组治疗后HR、MAP低于治疗前,24h尿量多于治疗前,且观察组HR、MAP低于对照组,24h尿量多于对照组(P<0.05)。两组治疗后LVEF、CO大于治疗前,LVEDD小于治疗前,且观察组LVEF、CO大于对照组,LVEDD小于对照组(P<0.05)。两组治疗后SAQ评分高于治疗前,SSQ-HF评分低于治疗前,且观察组SAQ评分高于对照组,SSQ-HF评分低于对照组(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论rh-BNP在冠心病DHF治疗中具有较高的有效性与安全性,可调节患者体征,改善其心功能,促使病情转归,且不增加不良反应。

Objective To study the safety and efficacy of recombinant human brain natriuretic peptide(rh-BNP)in the treatment of decompensated heart failure(DHF)of coronary heart disease.Methods From December 2020 to December 2022,60 patients with DHF of coronary heart disease admitted to Pingxiang Third People's Hospital were selected and divided into control group(30 patients)and observation group(30 patients)according to the random number table method.The control group was treated with routine treatment,and the observation group was treated with rh-BNP on the basis of routine treatment.The clinical efficacy,physical signs[heart rate(HR),mean arterial pressure(MAP),24-h urine volume],cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),cardiac output(CO)],severity of disease[Seattle angina questionnaire(SAQ),heart failure symptom status questionnaire(SSQ-HF)]and adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group(90.00%)was higher than that in the control group(73.33%)(P<0.05).After treatment,HR and MAP in the two groups were lower than those before treatment,and 24 h urine volume was more than that before treatment,HR and MAP in the observation group were lower than those in the control group,and 24 h urine volume was more than that in the control group(P<0.05).After treatment,LVEF and CO in the two groups were higher than those before treatment,LVEDD was lower than that before treatment,and LVEF and CO in the observation group were higher than those in the control group,LVEDD was lower than that in the control group(P<0.05).After treatment,the SAQ score of the two groups was higher than that before treatment,and the SSQ-HF score was lower than that before treatment,while the SAQ score of the observation group was higher than that of the control group,and the SSQ-HF score was lower than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion rh-BNP has high efficacy and safety in the treatment of DHF in coronary heart disease.Meanwhile,it can regulate the signs of patients,improve their cardiac function,promote the prognosis of the disease,and do not increase adverse reactions.